Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Janux Therapeutics Inc | JANX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 48.88 | 07:31:57 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 48.88 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 5.65 - 58.6936 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 48.88 | USD |
Janux Therapeutics (JANX) Options Flow Summary
Janux Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.53B | 51.66M | - | 8.08M | -58.29M | -1.13 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Janux Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical JANX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 52.10 | 52.33 | 44.71 | 48.94 | 667,201 | -3.22 | -6.18% |
| 1 Month | 38.90 | 56.27 | 34.63 | 45.98 | 830,743 | 9.98 | 25.66% |
| 3 Months | 9.46 | 58.6936 | 7.79 | 43.91 | 976,716 | 39.42 | 416.70% |
| 6 Months | 6.63 | 58.6936 | 5.65 | 39.59 | 516,537 | 42.25 | 637.25% |
| 1 Year | 15.57 | 58.6936 | 5.65 | 34.60 | 313,983 | 33.31 | 213.94% |
| 3 Years | 34.00 | 58.6936 | 5.65 | 28.65 | 184,800 | 14.88 | 43.76% |
| 5 Years | 34.00 | 58.6936 | 5.65 | 28.65 | 184,800 | 14.88 | 43.76% |
Janux Therapeutics Description
| Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer. |
